NASDAQ: SONNSonnet Biotherapeutics Holdings Inc Stock
$1.77+0.07 (+4.12%)
Updated Apr 18, 2024
SONN Price
$1.77
Fair Value Price
$1.84
Market Cap
$5.43M
52 Week Low
$1.08
52 Week High
$26.40
P/E
-0.18x
P/B
2.11x
P/S
51.16x
PEG
N/A
Dividend Yield
N/A
Revenue
$129.18k
Earnings
-$14.46M
Gross Margin
100%
Operating Margin
-11,193.3%
Profit Margin
-11,193.3%
Debt to Equity
1.08
Operating Cash Flow
-$19M
Beta
1.11
Next Earnings
May 8, 2024
Ex-Dividend
N/A
Next Dividend
N/A
SONN Overview
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SONN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SONN ($1.77) is undervalued by 3.71% relative to our estimate of its Fair Value price of $1.84 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
SONN ($1.77) is not significantly undervalued (3.71%) relative to our estimate of its Fair Value price of $1.84 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SONN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SONN due diligence checks available for Premium users.
Be the first to know about important SONN news, forecast changes, insider trades & much more!
SONN News
Valuation
SONN fair value
Fair Value of SONN stock based on Discounted Cash Flow (DCF)
Price
$1.77
Fair Value
$1.84
Undervalued by
3.71%
SONN ($1.77) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SONN ($1.77) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SONN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SONN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.18x
Industry
15.68x
Market
41.33x
SONN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.11x
Industry
5.76x
SONN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SONN's financial health
Profit margin
Revenue
$18.6k
Net Income
-$1.2M
Profit Margin
-6,273.5%
SONN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SONN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$5.3M
Liabilities
$2.8M
Debt to equity
1.08
SONN's short-term assets ($4.62M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SONN's short-term assets ($4.62M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SONN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SONN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.1M
Investing
$0.0
Financing
$3.8M
SONN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SONN vs Biotech Stocks
Sonnet Biotherapeutics Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.